Peng Huang

Also affiliated with Nankai University, Xi'an University of Technology, Zhejiang University, Tsinghua University

Biochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.”.

A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5574

N/A

0DataRank · unranked

4 citations

Mary Wilkinson, Lainie P. Martin, Amy Deery, Amanda Langsdale, Asnakech Bayable +6 more

Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101463

N/A

0DataRank · unranked

37 citations

Tatiana V. Karpinets, Sheeba J. Sujit, Mohamed Qayati, Pingjun Chen, Muhammad Aminu +32 more

Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer

Nature Communications(2024)10.1038/s41467-024-47242-3

N/A

0DataRank · unranked

3 citations

Jianhua Ling, Ching-Fei Li, Chi-Lin Tsai, Wenjuan Yin, Junwei Hou +26 more

PD-L1 pfeRNAs as blood-based predictors of treatment response of unresectable malignant pleural mesothelioma patients administered Durvalumab with cisplatin and pemetrexed as first-line therapy

Non-coding RNA Research(2025)10.1016/j.ncrna.2025.02.003

N/A

0DataRank · unranked

4 citations

Suguru Yamauchi, Kaitlyn Ecoff, Kristen Rodgers, James R. Eshleman, Charles Conover Talbot +7 more